SARS-CoV-2 variant B.1.617 is resistant to Bamlanivimab and evades antibodies induced by infection and vaccination

Publication date: Available online 29 June 2021Source: Cell ReportsAuthor(s): Markus Hoffmann, Heike Hofmann-Winkler, Nadine Krüger, Amy Kempf, Inga Nehlmeier, Luise Graichen, Prerna Arora, Anzhalika Sidarovich, Anna-Sophie Moldenhauer, Martin S. Winkler, Sebastian Schulz, Hans-Martin Jäck, Metodi V. Stankov, Georg M.N. Behrens, Stefan Pöhlmann

Source: Cell Reports - June 29, 2021 Category: Cytology Source Type: research